RT Journal Article
SR Electronic
T1 Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.04.21252528
DO 10.1101/2021.03.04.21252528
A1 Grint, Daniel J
A1 Wing, Kevin
A1 Williamson, Elizabeth
A1 McDonald, Helen I
A1 Bhaskaran, Krishnan
A1 Evans, David
A1 Evans, Stephen JW
A1 Walker, Alex J
A1 Hickman, George
A1 Nightingale, Emily
A1 Schultze, Anna
A1 Rentsch, Christopher T
A1 Bates, Chris
A1 Cockburn, Jonathan
A1 Curtis, Helen J
A1 Morton, Caroline E
A1 Bacon, Sebastian
A1 Davy, Simon
A1 Wong, Angel YS
A1 Mehrkar, Amir
A1 Tomlinson, Laurie
A1 Douglas, Ian J
A1 Mathur, Rohini
A1 Blomquist, Paula
A1 MacKenna, Brian
A1 Ingelsby, Peter
A1 Croker, Richard
A1 Parry, John
A1 Hester, Frank
A1 Harper, Sam
A1 DeVito, Nicholas J
A1 Hulme, Will
A1 Tazare, John
A1 Goldacre, Ben
A1 Smeeth, Liam
A1 Eggo, Rosalind M
YR 2021
UL http://medrxiv.org/content/early/2021/03/10/2021.03.04.21252528.abstract
AB The B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation of disease severity associated with this VOC is critical for pandemic planning. We found increased risk of death for VOC compared with non-VOC cases in England (HR: 1.67 (95% CI: 1.34 - 2.09; P<.0001)). Absolute risk of death by 28-days increased with age and comorbidities. VOC has potential to spread faster with higher mortality than the pandemic to date.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Council MR/V015737/1. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are stored in a secure platform and cannot be shared directly. Please see opensafely.org for access information.